Cathie's Ark Logo
Intellia Therapeutics Inc Logo

ARKK Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Gene TherapyGenomicsSynthetic BiologyGene Base EditingCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
May 2, 2023
BUY33.993k0.0188%ARKK
April 28, 2023
BUY307.0000.0002%ARKK
April 27, 2023
BUY13.695k0.0074%ARKK
April 26, 2023
BUY59.305k0.0318%ARKK
April 25, 2023
BUY58.163k0.03%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
3.38%$3.56b
🏋🏿‍♂️Weight Rank In ARKK🌏Country
15🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
15$62.04
🎫ARK Ownership Percent
7.84%
Description
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Website
intelliatx.com

Other ETFs That Hold NTLA

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.95%
ARKKARK Innovation ETF3.77%
GNOMGlobal X Genomics & Biotechnology ETF3.28%
XBISPDR® S&P Biotech ETF1.12%
IBBiShares Biotechnology ETF0.31%
LABUS&P Biotech Bull 3X Shares ETF0.24%

Research Notes and Commentary for NTLA

No Research Notes Found for NTLA